Please assess the completion status of the following clinical trial:

Trial Title: A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification~* Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory~* Have been treated with stable doses of metformin for at least 3 months~* Have a body mass index (BMI) ≥25 kilograms per square meter~Exclusion Criteria:~* Have type 1 diabetes (T1D)~* Have used any glucose-lowering medication other than metformin 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past~* Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke)~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial~* Have had chronic or acute pancreatitis any time prior to study entry~* Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation~* Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide 4.5mg (Type: EXPERIMENTAL): 4.5mg of Dulaglutide administered subcutaneously (SC)
- Dulaglutide 3.0mg (Type: EXPERIMENTAL): 3.0mg of Dulaglutide administered SC
- Dulaglutide 1.5mg (Type: ACTIVE_COMPARATOR): 1.5mg of Dulaglutide administered SC
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC

Based on this trial design, predict the completion outcome and termination type (if applicable).